WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a real-world study in eyes with geographic atrophy due to nonexudative age-related macular degeneration.
Ip, of Doheny Eye Center UCLA Arcadia, said the efficacy and safety findings for Syfovre (pegcetacoplan injection, Apellis) were “reassuring.” Results showed the rate of adverse effects was low.
“At least in one large private practice setting, the real-world results quite mirror what were seen in the phase 3 OAKS and DERBY clinical trials,” he told Healio.